Introduction: Sepsis is defined as life-threatening organ dysfunction in result of the host’s dysregulated response to infection and septic shock. Sepsis-associated kidney injury is usually defined as concurrent presence of acute kidney injury (AKI) and sepsis without other significant causative factors. Method: The current retrospective study was conducted to elucidate beneficial and side effects of CytoSorb®. A total of 17 patients were primarily treated with continuous renal replacement therapy in combination with CytoSorb. The demand for norepinephrine, mean arterial pressure, lactate, and procalcitonin (PCT) levels, as well as ICU length of stay, was measured. Result: The blood lactate levels decreased by 32.30% when comparing mean levels before and after treatment. All patients who survived (n = 14) had reduction in vasopressor demand to 68.96% of their initial dose before the start of treatment. Hospital survival was greater in patients who initially had higher vasopressor demand compared to their nonsurviving counterparts, but in whom vasopressor dosages were reduced significantly during their treatments. Mortality as predicted by APACHE II score in the overall patient population was 79.9%, whereas, the observed ICU mortality was 31%. The baseline PCT levels on patients received 1, 2, and 3 CytoSorbs were 27.08 ± 5.81 ng/mL, 13.28 ± 2.62 ng/mL, and 21.03 ± 6.56 ng/mL, respectively. Observed PCT levels at 24 h after the last treatment on patients received 1, 2, and 3 CytoSorb were 31.55 ± 15.70 ng/mL, 5.61 ± 1.77 ng/mL, and 8.11 ± 3.62 ng/mL, respectively. Conclusion: In conclusion, it seems that applying the CytoSorb in combination with CRRT in ICU septic patients with AKI, is related to a significant decrease in mortality, if the integrity and continuity of the treatment be kept, as much as possible. This study presented an effectively positive outcome with cytokine adsorber treatment as an adjuvant along with standard treatment in a high-risk mortality case of septic shock with organ failure.

1.
Singer
M
,
Deutschman
CS
,
Seymour
CW
,
Shankar-Hari
M
,
Annane
D
,
Bauer
M
,
The Third international consensus definitions for sepsis and septic shock (Sepsis-3)
.
JAMA
.
2016
;
315
(
8
):
801
10
.
2.
Singh
Y
,
Chhabra
S
,
Lashkari
K
,
Taneja
A
,
Garg
A
,
Chandra
A
,
Hemoadsorption by extracorporeal cytokine adsorption therapy (CytoSorb®) in the management of septic shock: a retrospective observational study
.
Int J Art Organ
.
2020
;
43
(
6
):
372
8
.
3.
Rimmelé
T
,
Kellum
JA
.
Clinical review: blood purification for sepsis
.
Criti Care
.
2011
;
15
(
1
):
1
10
.
4.
Angus
DC
,
van der Poll
T
.
Severe sepsis and septic shock
.
N Engl J Med
.
2013
;
369
(
9
):
840
51
. .
5.
Engel
C
,
Brunkhorst
FM
,
Bone
H-G
,
Brunkhorst
R
,
Gerlach
H
,
Grond
S
,
Epidemiology of sepsis in Germany: results from a national prospective multicenter study
.
Inten Care Med
.
2007
;
33
(
4
):
606
18
.
6.
Wiegele
M
,
Krenn
CG
.
Cytosorb™ in a patient with legionella pneumonia associated rhabdomyolysis: a case report
.
Asaio J
.
2015
;
61
(
3
):
e14
e6
.
7.
Peerapornratana
S
,
Manrique-Caballero
CL
,
Gómez
H
,
Kellum
JA
.
Acute kidney injury from sepsis: current concepts, epidemiology, pathophysiology, prevention and treatment
.
Kidney Int
.
2019
;
96
(
5
):
1083
99
. .
8.
Bellomo
R
,
Kellum
JA
,
Ronco
C
,
Wald
R
,
Martensson
J
,
Maiden
M
,
Acute kidney injury in sepsis
.
Inten Care Med
.
2017
;
43
(
6
):
816
28
.
9.
Godin
M
,
Murray
P
,
Mehta
RL
.
Clinical approach to the patient with AKI and sepsis
.
Semi Nephrol
.
2015
;
35
(
1
):
12
.
10.
Mitzner
SR
,
Gloger
M
,
Henschel
J
,
Koball
S
.
Improvement of hemodynamic and inflammatory parameters by combined hemoadsorption and hemodiafiltration in septic shock: a case report
.
Blood Purif
.
2013
;
35
(
4
):
314
5
. .
11.
Hetz
H
,
Berger
R
,
Recknagel
P
,
Steltzer
H
.
Septic shock secondary to β-hemolytic streptococcus-induced necrotizing fasciitis treated with a novel cytokine adsorption therapy
.
London, England
:
SAGE Publications Sage UK
;
2014
.
12.
Born
F
,
Pichlmaier
M
,
Peterss
S
,
Khaladj
N
,
Hagl
C
.
Systemic inflammatory response syndrome in der Herzchirurgie: Neue Therapiemöglichkeiten durch den Einsatz eines Cytokin-Adsorbers während EKZ
.
Kardiotechnik
.
2014
;
2
:
41
6
.
13.
Kellum
JA
,
Song
M
,
Venkataraman
R
.
Hemoadsorption removes tumor necrosis factor, interleukin-6, and interleukin-10, reduces nuclear factor-kappaB DNA binding, and improves short-term survival in lethal endotoxemia
.
Crit Care Med
.
2004
;
32
(
3
):
801
5
. .
14.
De Backer
D
,
Dorman
T
.
Surviving sepsis guidelines: a continuous move toward better care of patients with sepsis
.
JAMA
.
2017
;
317
(
8
):
807
8
. .
15.
Chadban
SJ
,
Ahn
C
,
Axelrod
DA
,
Foster
BJ
,
Kasiske
BL
,
Kher
V
,
Summary of the kidney disease: improving global outcomes (KDIGO) clinical practice guideline on the evaluation and management of candidates for kidney transplantation
.
Transplantation
.
2020
;
104
(
4
):
708
14
.
16.
Rivers
E
,
Nguyen
B
,
Havstad
S
,
Ressler
J
,
Muzzin
A
,
Knoblich
B
,
Early goal-directed therapy in the treatment of severe sepsis and septic shock
.
N Eng J Med
.
2001
;
345
(
19
):
1368
77
.
17.
Honore
PM
,
Joannes-Boyau
O
.
High volume hemofiltration (HVHF) in sepsis: a comprehensive review of rationale, clinical applicability, potential indications and recommendations for future research
.
Int J Artif Organs
.
2004
;
27
(
12
):
1077
82
. .
18.
Machado
FR
,
Cavalcanti
AB
,
Bozza
FA
,
Ferreira
EM
,
Carrara
FSA
,
Sousa
JL
,
The epidemiology of sepsis in Brazilian intensive care units (the sepsis prevalence assessment database, SPREAD): an observational study
.
Lancet Infect Dis
.
2017
;
17
(
11
):
1180
9
.
19.
Shankar-Hari
M
,
Ambler
M
,
Mahalingasivam
V
,
Jones
A
,
Rowan
K
,
Rubenfeld
GD
.
Evidence for a causal link between sepsis and long-term mortality: a systematic review of epidemiologic studies
.
Crit Care
.
2016
;
20
(
1
):
101
13
. .
20.
Harrison
AM
,
Gajic
O
,
Pickering
BW
,
Herasevich
V
.
Development and implementation of sepsis alert systems
.
Clin Chest Med
.
2016
;
37
(
2
):
219
29
. .
21.
Kogelmann
K
,
Jarczak
D
,
Scheller
M
,
Drüner
M
.
Hemoadsorption by CytoSorb in septic patients: a case series
.
Crit Care
.
2017
;
21
(
1
):
74
10
. .
22.
Lopes
JA
,
Jorge
S
.
The RIFLE and AKIN classifications for acute kidney injury: a critical and comprehensive review
.
Clin Kidney J
.
2012
;
6
(
1
):
8
14
. .
23.
Gruda
MC
,
Ruggeberg
K-G
,
O’Sullivan
P
,
Guliashvili
T
,
Scheirer
AR
,
Golobish
TD
,
Broad adsorption of sepsis-related PAMP and DAMP molecules, mycotoxins, and cytokines from whole blood using CytoSorb® sorbent porous polymer beads
.
PloS One
.
2018
;
13
(
1
):
e0191676
.
24.
Malard
B
,
Lambert
C
,
Kellum
JA
.
In vitro comparison of the adsorption of inflammatory mediators by blood purification devices
.
Intensive Care Med Exp
.
2018
;
6
(
1
):
12
3
. .
25.
Namas
RA
,
Namas
R
,
Lagoa
C
,
Barclay
D
,
Mi
Q
,
Zamora
R
,
Hemoadsorption reprograms inflammation in experimental gram-negative septic peritonitis: insights from in vivo and in silico studies
.
Mol Med
.
2012
;
18
(
10
):
1366
74
.
26.
Tsertsvadze
A
,
Royle
P
,
Seedat
F
,
Cooper
J
,
Crosby
R
,
McCarthy
N
.
Community-onset sepsis and its public health burden: a systematic review
.
Syst Rev
.
2016
;
5
(
1
):
81
19
. .
27.
Annane
D
,
Aegerter
P
,
Jars-Guincestre
MC
,
Guidet
B
.
Current epidemiology of septic shock: the CUB-Rea Network
.
Am J Res Crit Care Med
.
2003
;
168
(
2
):
165
72
.
28.
Tetta
C
,
Bellomo
R
,
Inguaggiato
P
,
Wratten
ML
,
Ronco
C
.
Endotoxin and cytokine removal in sepsis
.
Ther Apher
.
2002
;
6
(
2
):
109
15
. .
29.
Uzzan
B
,
Cohen
R
,
Nicolas
P
,
Cucherat
M
,
Perret
GY
.
Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis
.
Crit Care Med
.
2006
;
34
(
7
):
1996
2003
. .
30.
Charles
PE
,
Tinel
C
,
Barbar
S
,
Aho
S
,
Prin
S
,
Doise
JM
,
Procalcitonin kinetics within the first days of sepsis: relationship with the appropriateness of antibiotic therapy and the outcome
.
Crit Care
.
2009
;
13
(
2
):
1
11
.
31.
Tsangaris
I
,
Plachouras
D
,
Kavatha
D
,
Gourgoulis
GM
,
Tsantes
A
,
Kopterides
P
,
Diagnostic and prognostic value of procalcitonin among febrile critically ill patients with prolonged ICU stay
.
BMC Infect Dis
.
2009
;
9
(
1
):
1
8
.
32.
Hawchar
F
,
Molnar
Z
.
Interpreting biomarkers in infectious diseases in intensive care unit: the potential role of procalcitonin
.
J Emerg Crit Care Med
.
2018
:
2
.
33.
Bruenger
F
,
Kizner
L
,
Weile
J
,
Morshuis
M
,
Gummert
JF
.
First successful combination of ECMO with cytokine removal therapy in cardiogenic septic shock: a case report
.
London, England
:
SAGE Publications Sage UK
;
2015
.
34.
Träger
K
,
Fritzler
D
,
Fischer
G
,
Schröder
J
,
Skrabal
C
,
Liebold
A
,
Treatment of post-cardiopulmonary bypass SIRS by hemoadsorption: a case series
.
Int J Art Organ
.
2016
;
39
(
3
):
141
6
.
35.
Peng
ZY
,
Carter
MJ
,
Kellum
JA
.
Effects of hemoadsorption on cytokine removal and short-term survival in septic rats
.
Crit Care Med
.
2008
;
36
(
5
):
1573
. .
36.
Schädler
D
,
Pausch
C
,
Heise
D
,
Meier-Hellmann
A
,
Brederlau
J
,
Weiler
N
,
The effect of a novel extracorporeal cytokine hemoadsorption device on IL-6 elimination in septic patients: a randomized controlled trial
.
PloS One
.
2017
;
12
(
10
):
e0187015
.
37.
Angheloiu
AA
,
Angheloiu
GO
.
Removal of dabigatran using sorbent hemadsorption
.
Int J Cardiol
.
2019
;
293
:
73
5
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.